Kennedy Ferruggia, Assistant Editor

Rilonacept offers a targeted approach to treating recurrent pericarditis by blocking IL-1 inflammatory pathways.

New research analyzes human challenge infection studies to reveal insights on respiratory syncytial virus viral load and symptom dynamics, aiding treatment development.

Patients with diabetes using glucagon-like peptide-1 (GLP-1) drugs face double the risk of developing neovascular age-related macular degeneration, highlighting crucial ocular health concerns.

Pharmacists navigate reimbursement challenges while advocating for legislative support and innovative models to enhance patient care and financial sustainability.

New research highlights vitamin D's potential to slow telomere shortening, suggesting it may combat aging and promote cellular health.

Although women might benefit from fattier breakfasts, men could respond best to carbohydrates.

New findings show LYR-210's potential to significantly alleviate chronic rhinosinusitis symptoms, offering hope for patients with nasal inflammation and polyps.

Clairity Breast's FDA-approved AI platform revolutionizes breast cancer risk prediction, enhancing early detection and personalized prevention strategies.

Electronic prior authorization (EPA) technology can streamline the complex process of obtaining prior authorizations for GLP-1 medications.

Zongertinib shows promising efficacy and safety for HER2-mutant NSCLC, with a 71% response rate and low toxicity, paving the way for future treatments.

The FDA designated Hadlima as an interchangeable biosimilar to Humira, enhancing patient access and potential savings for various conditions.

A study of early-onset colorectal cancer found significant racial disparities, with younger patients more frequently diagnosed at advanced stages.

The FDA grants fast track designation to TEV-53408, a promising treatment for celiac disease designed to address gluten intolerance and improve patient outcomes.

New research highlights the significant cardiovascular risks associated with RSV, emphasizing the need for vaccination to protect vulnerable populations.

The FDA approved the MenQuadfi vaccine for young children, enhancing protection against invasive meningococcal disease and its severe complications.

The expert explored the complex prior authorization process for GLP-1 medications, discussing challenges in documentation and medical necessity.

RSV vaccines for pregnant women and infants require careful timing and administration.

Orforglipron showed promising results in managing type 2 diabetes, offering a potential oral alternative to injectable treatments.

Embedding a pharmacist in the dermatology clinic improved clinical and financial outcomes.

Ranibizumab injection (Susvimo; Genentech) could offer long-lasting vision preservation and reduce the need for frequent injections in patients with diabetic retinopathy.

Yuflyma gains FDA interchangeability with Humira, enhancing patient access to effective biosimilar treatments for various inflammatory conditions.

Experts emphasize the importance of tailored vaccination strategies for pneumococcal based on individual risk factors.

RSV vaccination for older adults requires understanding risk factors, using empathetic communication strategies, and proactively identifying eligible patients through careful review of medical histories and care transitions.

Research reveals pioglitazone, a diabetes drug, may slow prostate cancer progression, offering new hope for patients with both conditions.

A new triple-combination therapy shows promise in improving asthma management, offering hope for millions with uncontrolled symptoms.

New research highlights the effectiveness and safety of RSV vaccines for older adults, revealing critical insights into vaccination benefits and risks.

A study reveals sasanlimab enhances event-free survival in high-risk bladder cancer patients, offering new hope against disease recurrence.

Cure Rare Disease's CRD-002 receives FDA orphan drug designation, advancing hope for SCA3 treatment with innovative oligonucleotide therapy.

Tirzepatide outperforms semaglutide in weight loss, achieving an average reduction of 20.2% in a pivotal trial for obesity management.